A naukri.com initiative
Bioengineer
2w
81
Image Credit: Bioengineer
Outcome Risk Associated Clonal Lung Expression
- ORACLE is a clonal expression biomarker that has the potential to redefine prognostic precision in lung adenocarcinoma (LUAD).
- The ORACLE biomarker emerged from the TRACERx study and it offers a robust and reproducible method for risk stratification based on molecular fingerprints rather than spatially confined snapshots of tumor biology.
- ORACLE’s validation resolves the issue of intratumor heterogeneity (ITH) that plagues traditional single-site biopsies as it demonstrated concordant classification across tumor regions.
- ORACLE’s ability to outperform traditional tumor-node-metastasis (TNM) staging criteria in predicting survival highlights its potential to guide decisions regarding adjuvant therapy.
- ORACLE identifies molecular fingerprints of lethal metastatic clones and its association with chromosomal instability and complexity sheds light on its predictive capacity for chemotherapy sensitivity.
- ORACLE is a concise 23-transcript assay that not only simplifies the assessment of evolutionary dynamics but also complements other biomarkers, providing a multidimensional view of tumor behavior and prognostic outcomes.
- ORACLE’s predictive capabilities for chemotherapy response could inform future clinical trials aimed at refining adjuvant therapy decisions and paving the way for precision diagnostics in lung cancer.
- ORACLE represents the potential of clonal expression biomarkers in cancer diagnostics as it offers a scalable and impactful tool to improve patient outcomes.
- While ORACLE represents a significant leap forward, it is essential to acknowledge the complexities of cancer biology that remain beyond its reach.
- ORACLE is poised to reshape the landscape of lung cancer care, offering hope for improved survival and personalized treatment strategies.
Read Full Article
4 Likes
For uninterrupted reading, download the app